推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-34243363,021-33363733

chinasupport@letpub.com

登录 注册 新注册优惠

OncoTargets and Therapy 期刊收藏夹

2026年6月最新影响因子数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

期刊名:   ISSN:   研究方向:   IF范围: -   SCI收录:
大类学科:   小类学科:   新锐期刊分区表:   是否OA期刊:   结果排序:
热门AI工具: 论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重 论文讨论生成 参考文献挖掘工具 审稿意见辅助撰写
查看更多AI工具 >>
智能期刊推荐助手

推荐偏好:

 
AI写作痕迹消减工具

 

近期推荐:
热
全流程投稿协助套餐服务
热
SCI论文AI润色+人工QC服务
热
Springer Nature特刊征稿

按研究方向查看:


OncoTargets and Therapy期刊基本信息Hello,您是该期刊的第174918位访客

基本信息 登录收藏
期刊名字OncoTargets and TherapyOncoTargets and Therapy

ONCOTARGETS THER
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
4.9
52人评分
我要评分

声誉
3.5

影响力
5.2

速度
9.2

期刊ISSN1178-6930
安装APP,查看期刊最新消息
iOS版下载安装安卓版下载安装
2025-2026最新IF
(数据来源于网友提供)
注册或登录后,查看IF
实时影响因子 截止2026年9月20日:1.775
2025-2026自引率0.0%点击查看自引率趋势图
五年IF
(数据来源于网友提供)
2.701数据由网友[sunny_cosmos_346]收集提供
h-index 44
CiteScore
( 2026年6月最新版)
CiteScoreSJRSNIPCiteScore排名
4.700.8000.730
学科分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q2108 / 278
大类:Medicine
小类:Oncology
Q2172 / 428

期刊简介
OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents
-Novel therapeutic regimens for improved benefit and/or decreased side effects
-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.
-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.
-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.
-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Single nucleotide polymorphism (SNP) studies will not be considered.
期刊官方网站https://www.dovepress.com/oncotargets-and-therapy-journal
期刊投稿格式模板
VIP专享
Word版格式模板  
此模板来自于期刊/出版社官网。开通VIP可免费下载,并享1w+期刊模板资源。
 
期刊投稿网址https://www.dovepress.com/submit_step_1.php
该期刊中国学者近期发文 - NewClinical Efficacy and Safety of Pembrolizumab-Based Therapy in Recurrent or Advanced Cervical Cancer: A Systematic Review and Meta-Analysis
Author: Tan, Bing; Lin, Shike; Wei, Xian; Chen, Shengcai; Liang, Yuexiu; Deng, Yan
Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S612659


ELOVL6 Promotes the Proliferation and Migration of Oral Squamous Cell Carcinoma Cells Through Fatty Acid Remodelling and ROS Modulation in vitro
Author: You, Jing; Li, Liuyang; Yang, Jingjing; Xu, Juanyong; Qian, Bo; Qian, Ling
Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S592523


Small Nucleolar RNAs (snoRNAs) in Cancer: From Biogenesis to Clinical Potential
Author: Zhang, Han; He, Chunli; Chen, Dan; Feng, Jing; He, Xueqin; Zhang, Zhang
Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S600733


Sintilimab-Induced Sequential Multi-System Severe Immune-Related Adverse Events in an Elderly Patient with Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review
Author: Xia, Xi; Yu, Ting; Sun, Hui; Li, Jian; Liu, Fengjun; Zhu, Xin
Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S606668


期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足OncoTargets and Therapy的语言要求,还能让OncoTargets and Therapy编辑和审稿人得到更好的审稿体验,让稿件最大限度地被OncoTargets and Therapy编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(11篇) 。
提交文稿
是否OA开放访问Yes
OA期刊相关信息
文章处理费:需要( USD2990; )
文章处理费豁免:查看说明
其他费用:没有
期刊主题关键词:oncology、cancer、therapeutic agents
相关链接:Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
通讯方式PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752
出版商Dove Medical Press Ltd.
涉及的研究方向BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY
出版国家或地区ENGLAND
出版语言English
出版周期
出版年份2008
年文章数 98点击查看年文章数趋势图
Gold OA文章占比98.47%
研究类文章占比:
文章 ÷(文章 + 综述)
82.65%
WOS期刊JCR分区
( 2025-2026年最新版)
注册或登录后,查看WOS分区等级
期刊分区表预警名单 2026年03月发布的新锐学术版:不在预警名单中

2025年03月发布的2025版:不在预警名单中

2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:预警等级:中

2020年12月发布的2020版:预警等级:中
《新锐期刊分区表》
( 2026年3月发布)
点击查看期刊分区表趋势图
大类学科小类学科Top期刊综述期刊
医学 4区3区3区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
生物工程与应用微生物
3区2区3区
ONCOLOGY
肿瘤学
2区4区3区
否N/A
期刊分区表
( 2025年3月升级版)
大类学科小类学科Top期刊综述期刊
医学 3区4区2区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
生物工程与应用微生物
4区2区4区
ONCOLOGY
肿瘤学
4区4区4区
否否
期刊分区表
( 2023年12月旧的升级版)
大类学科小类学科Top期刊综述期刊
医学 1区4区4区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
生物工程与应用微生物
1区1区3区
ONCOLOGY
肿瘤学
2区2区4区
否否
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
Directory of Open Access Journals (DOAJ)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1178-6930%5BISSN%5D
平均审稿速度网友分享经验:
较慢,6-12周
平均录用比例网友分享经验:
较易
版面费/APC文章处理费信息
文章处理费:需要( USD2990; )
文章处理费豁免:查看说明
其他费用:没有
LetPub提供文章处理费(APC)支持服务,可以用人民币支付版面费啦!
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在OncoTargets and Therapy顺利发表。
快看看作者怎么说吧:服务好评 论文致谢(11篇) 。
提交文稿
期刊常用信息链接
同领域相关期刊 OncoTargets and Therapy期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 OncoTargets and Therapy期刊分区表趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
OncoTargets and Therapy上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 期刊分区表趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 期刊分区表相关期刊
  • 同类著名期刊名称 h-index CiteScore
    Nature Cancer038.50
    JAMA Oncology6132.60
    JAMA Oncology4132.60
    Trends in Cancer030.80
    Experimental Hematology & Oncology019.60
    Cancer Biology & Medicine2911.50
    ESMO Open012.00
    Liver Cancer2517.00
    Cancer Pathogenesis and Therapy06.20
    Annual Review of Cancer Biology010.00
    期刊分区表同大类学科的热搜期刊 浏览次数
    MEDICINE923308
    JOURNAL OF ETHNOPHARMACOLOGY823929
    Frontiers in Immunology776162
    BIOMEDICINE & PHARMACOTHERAPY742692
    Frontiers in Pharmacology739870
    BIOMATERIALS731060
    PHYTOMEDICINE669078
    Frontiers in Oncology637711
    Biomedical Signal Processing and Control627703
    IEEE Journal of Biomedical and Health Informatics619521
  •  

    OncoTargets and Therapy OncoTargets and Therapy
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Clinical Efficacy and Safety of Pembrolizumab-Based Therapy in Recurrent or Advanced Cervical Cancer: A Systematic Review and Meta-Analysis

    Author: Tan, Bing; Lin, Shike; Wei, Xian; Chen, Shengcai; Liang, Yuexiu; Deng, Yan
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S612659
        DOI
    2.ELOVL6 Promotes the Proliferation and Migration of Oral Squamous Cell Carcinoma Cells Through Fatty Acid Remodelling and ROS Modulation in vitro

    Author: You, Jing; Li, Liuyang; Yang, Jingjing; Xu, Juanyong; Qian, Bo; Qian, Ling
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S592523
        PubMed      DOI
    3.Small Nucleolar RNAs (snoRNAs) in Cancer: From Biogenesis to Clinical Potential

    Author: Zhang, Han; He, Chunli; Chen, Dan; Feng, Jing; He, Xueqin; Zhang, Zhang
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S600733
        PubMed      DOI
    4.Sintilimab-Induced Sequential Multi-System Severe Immune-Related Adverse Events in an Elderly Patient with Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review

    Author: Xia, Xi; Yu, Ting; Sun, Hui; Li, Jian; Liu, Fengjun; Zhu, Xin
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S606668
        PubMed      DOI
    5.Primary Hepatic Epithelioid Gastrointestinal Stromal Tumor: A Rare Case

    Author: Yang, Qijun; Fang, Xixi; Wang, Lingling; Lu, Jun
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S613626
        PubMed      DOI
    6.A Nomogram Integrating HOXA9 Expression and Clinicopathological Factors for Predicting Postoperative Recurrence in Gastric Cancer: A Single-Center Retrospective Study

    Author: Weng, Jianze; Ying, Jingwen; Xia, Minming; Xie, Yijie
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S596270
        PubMed      DOI
    7.Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

    Author: Zhang, Kaiyuan; Ren, Yanche
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S614003
        PubMed      DOI
    8.Multi-Omics Analysis Identifies Phosphoglucomutase 2 as a Potential Target to Alleviate Chemoradiotherapy Resistance in Cervical Cancer Cells

    Author: Yang, Huaxiang; Zheng, Qing; Li, Xin; Wang, Jingzhi
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S613657
        PubMed      DOI
    9.Advances in the Treatment of Breast Cancer at Different Stages of Pregnancy

    Author: Lv, Jiajin; Lin, Xu
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S586690
        PubMed      DOI
    10.Research on Targeted Therapy for Malignant Tumors of the Biliary Tract

    Author: Yang, Yuxin; Zhong, Hutianyu; Zhang, Jingjing; Wang, Peng
    Journal: ONCOTARGETS AND THERAPY. 2026; Vol. 19, Issue , pp. -. DOI: 10.2147/OTT.S593457
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144649.80
    LANCET70092.40
    MMWR Surveillance Summaries093.20
    Nature Reviews Clinical Oncology127126.60
    NATURE REVIEWS DRUG DISCOVERY289159.20
    NEW ENGLAND JOURNAL OF MEDICINE93374.80
    Signal Transduction and Targeted Therapy081.60
    ANNALS OF ONCOLOGY21069.60
    Nature Reviews Disease Primers4871.30
    World Psychiatry6184.80
    同分区等级的其他期刊名称 h-index CiteScore
    Foundations and Trends in Computer Graphics and Vision032.80
    PROGRESS IN REACTION KINETICS AND MECHANISM2321.60
    Journal of Obesity & Metabolic Syndrome014.40
    Advanced Sensor and Energy Materials03.70
    Business & Information Systems Engineering018.50
    Business & Information Systems Engineering018.50
    Battery Energy015.10
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM425.50
    PROGRESS IN PHOTOVOLTAICS11518.50
    Degenerative Neurological and Neuromuscular Disease00.00
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:
投稿前担心稿件结构或语言不够规范?试试稿件自查工具,一键检测 >>
与期刊沟通模版下载中心
VIP专享
掌握投稿全流程专业邮件模板,让您的学术沟通高效得体,显著提升论文发表效率!开通VIP可免费下载。
投稿信 (Cover Letter) 模板 回复信 (Response Letter) 模板 投稿状态查询 (Inquiry Letter) 模板
返修延期交稿 (Requesting Extension) 模板 变更作者信息申请 (Author Changes) 模板 拒稿后申诉信 (Appeal Letter) 模板
撤稿申请 (Withdrawal Request Letter) 模板 更正/勘误说明 (Corrigendum/Erratum) 模板 投稿前咨询信 (Pre-submission Inquiry) 模板
没有机构邮箱的说明 (Lack of institutional Email) 模板 更新中...

同领域作者分享投稿经验:共1251条


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2026 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室